Comparison baseline 
In survivors most measurements improved from baseline to follow-up at week 48; the rate of improvement did not differ between groups. The median CD4+ cells count was 69 cells/mL (IQR 36–119) at baseline and 179 cells/mL (IQR 132–516) at week-48. The median CD8+ at baseline was 715 cells/mL (IQR 395–1178) and 639 cells/mL (IQR 639–673) at week-48. The median CD4+/CD8+ ratio was 0.1 (IQR 0.05–0.22) at baseline and 0.34 (0.16–0.48) at week-48.At baseline, the median of IL-6 was higher for the EG than for the CG: 22 pg/ml; (IQR 15.5–43.9) vs 14 pg/ml, (IQR10.4–23.7); p = 0.02) (normal <3.4 pg/ml); 